Fig. 5: Correlations of antibody features with virological outcomes.

A SF162 and Mos1-gp140-specific IgG3 levels differences at week 50 between vaccinated animals with early (within 14 days from ARTI) or delayed viral rebound. Means with interquartile ranges are shown in boxplots. Dots are color coded to reflect different groups. Asterisks indicate statistically significant differences between the groups using Mann–Whitney’s U test (*, P ≤ 0.01; **, P ≤ 0.001; ***, P ≤ 0.0001) MFI, mean fluorescence intensity (B) Spearman’s rho correlation of Fcγ−R binding activity (measured at week 68, concurrent with PGT121 administration) and of T‑cell and ELISA responses (measured at week 74) with days to viral rebound. C Spearman’s rho correlation of AUC summations of antibody features with time to viral rebound. D Spearman’s rho correlation of all available time‑points for antibody effector functions (System Serology), clade C and group M mosaic Env binding antibody levels, and T‑cell responses (breadth and Gag/Pol/Env magnitude) with viral‑load setpoint. E Heatmap of the difference between indirect (mediated) and direct effects of the different immune features, where rows represent potential mediators (T‑cell magnitude and breadth, bidning antibody titers by ELISA) and columns represent biophysical and Fc‑effector features; positive values (red) indicate larger indirect effects, negative values (black) indicate larger direct effects.